Boehringer Ingelheim

Ingelheim, Germany & Shanghai, China | April 15, 2026 Boehringer Ingelheim and Zai Lab have announced a strategic clinical...

INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...

LYON, France, April 09, 2026 Boehringer Ingelheim has announced its continued support for Ecuador’s national effort to eliminate dog-mediated...

INGELHEIM, Germany, April 9, 2026 Boehringer Ingelheim has announced a strategic clinical trial collaboration with BioNTech to evaluate a...

Ingelheim, Germany | January 29, 2026 — Boehringer Ingelheim announced positive results from a 12-week Phase II clinical trial...

Ingelheim, Germany, November 28, 2025 Boehringer Ingelheim has announced a strategic leadership expansion with the appointment of Harsha Deshmukh...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for HERNEXEOS®...